Research demonstrates the impact of incretin therapies on cardiovascular health in individuals with diabetes and obesity, indicating a need for continued lifestyle management.
While incretin therapies represent a transformative advancement in cardiometabolic care, challenges remain-including gastrointestinal side effects, adherence issues, lean mass loss and cost. As next-generation agents (e.g. triple agonists) advance, lifestyle interventions remain essential for durable, management of diabetes, obesity and associated cardiovascular conditions.
No takes yet. Share an insight, caveat, or question.
A. Avogaro (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: